Ads
related to: lucrin injection for prostate cancer every 6 months bi annually chart printable- Case Studies
Review real case studies
with real patients.
- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Contact Us
Contact our representatives
for product and reimbursement info.
- Case Studies
Search results
Results from the WOW.Com Content Network
Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
LDR prostate brachytherapy (seed or line source implantation) is a proven treatment for low to high risk localized prostate cancer (when the cancer is contained within the prostate). [ 4 ] [ 5 ] Under a general anaesthetic, the radioactive seeds are injected through fine needles directly into the prostate , so that the radiotherapy can destroy ...
If the cancer has spread beyond the prostate, treatment options change significantly, so most doctors who treat prostate cancer use a variety of nomograms to predict the probability of spread. Treatment by watchful waiting/active surveillance, HIFU, external-beam radiation therapy, brachytherapy, cryosurgery, and surgery are, in general ...
Primary indications include endometriosis, [5] for the reduction of uterine fibroids, to treat prostate cancer, and to treat male hypersexuality with severe sexual deviation. [4] The drug has also been used off label to delay puberty in patients with gender dysphoria. [6] It was patented in 1975 and approved for medical use in 1986. [7]
Goserelin, sold under the brand name Zoladex among others, is a medication which is used to suppress production of the sex hormones (testosterone and estrogen), particularly in the treatment of breast cancer and prostate cancer. [2] [3] It is an injectable gonadotropin releasing hormone agonist (GnRH agonist). Structurally, it is a decapeptide.
Ads
related to: lucrin injection for prostate cancer every 6 months bi annually chart printable